Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can changing your vape flavor lower inflammation?

NCT ID NCT05423340

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether switching from banned e-cigarette flavors (like fruit or candy) to a tobacco flavor or using nicotine pouches could reduce signs of inflammation in daily vapers. 163 participants were randomly assigned to one of these options. The goal was to see if these changes could lower health risks associated with vaping.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
E-cigarette flavor (tobacco) and tobacco-free nicotine pouches
What this could lead to
If switching to less toxic flavors reduces inflammation, it could point toward safer ways to use nicotine products.
What could go wrong
This is a small, completed trial with no long-term follow-up. The results may not apply to all vapers, and switching flavors may not lower health risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

163 people

The number who actually took part.

Started

Jun 2022

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ENDS users as determined by: (a) using banned flavored ENDS with nicotine such as fruit, candy, dessert flavors, and/or any product that indicates such flavors (b) using ENDS daily, regularly for the past 6 months (self-reported). * No smoking tobacco or using smokeless tobacco for the past 6 months. * Subjects should be free of acute respiratory illness within the proceeding 30 days prior to recruitment (self-reported). * Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure. * After receiving information regarding the NYS flavor ban individuals must not want to quit vaping or stop using their flavored product for the next 90 days. Exclusion Criteria: * Individuals with health conditions and therapies that may affect immune responses and levels of inflammatory markers, including allergic rhinitis, aspirin/NSAID therapy, asthma, immunodeficiency (HIV or other), Guillain-Barre Syndrome, COPD, or fever/respiratory illness within 30 days prior to entry into study (self-reported). * Pregnant or nursing female participants (self-reported on telephone screener, pregnancy test on Visit#1) * Unable to communicate in English. * Unable or unwilling to follow protocol requirements. * Self-report having active, untreated medical/psychiatric conditions. * History of serious side effects from nicotine or from any nicotine replacement therapies. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Vulnerable populations, such as cognitively impaired adults, individuals who are not yet adults, pregnant women, and prisoners. * Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug. * After receiving information about the NYS flavor ban, participants who report that they are thinking about quitting or stop using their flavor within the next 90 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Electronic cigarette use are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Vaping

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, 14206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.